



# GASTRIC CANCER (GC)

## GLOBAL CLINICAL TRIAL LANDSCAPE (2024)

**#DYK**  
Did you know?

GC is the **5th most diagnosed cancer** and the **5th leading cause of cancer mortality**, characterized by uncontrolled cell growth in the stomach wall



Marketed drugs **emphasize antibody therapies** targeting HER2 (e.g., trastuzumab) and **immune checkpoint inhibitors** like PD-1/PD-L1 inhibitors (e.g., pembrolizumab, nivolumab)




Phase III trials are **advancing immunotherapy options and antibody-drug conjugates** (e.g., trastuzumab emtansine), showing **promising advancement** in GC treatment

### GASTRIC CANCER TRIAL CONTRIBUTIONS



The **U.S. and Asia-Pacific** region show similar recruitment rates



The content of this publication is proprietary to Novotech Health Holdings. No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of Novotech except in the case of quotations embodied in reviews and non-commercial uses. Please note that this copyright statement applies specifically to this publication and its content and does not extend to other materials or intellectual property owned by Novotech. Any unauthorized reproduction or distribution of this publication or any portion thereof may result in legal action taken by Novotech to protect its rights. For permissions or inquiries, please contact: [communications@novotech-cro.com](mailto:communications@novotech-cro.com)